需要氧气支持的COVID-19患者的Ozanimod疗法:一个随机的开放标签试验试验
François Lellouche1, Pascale Blais-Lecours2, François Maltais1
1Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Quebec City, QC, Canada; Department of Medicine, Université Laval, Quebec City, QC, Canada.
Chest
|October 28, 2023
概括
氨酸-1-酸盐受体配体 (SRLs) 显示出治疗病毒性肺炎的潜力. 在COVID-19患者的ozanimod (OZA) 干预是安全的,尽管在这个试点研究中,临床益处在统计学上并不显著.
科学领域:
- 免疫学和药理学
- 传染性疾病 传染性疾病
- 临床试验 临床试验
背景情况:
- 在病毒性肺炎模型中,氨酸-1-酸盐受体连接体 (SRL) 证明了在减轻免疫病理损伤方面的有效性.
- 该研究调查了给急性SARS-CoV-2感染的患者施用SRL治疗,特别是ozanimod (OZA) 的可行性.
研究的目的:
- 评估ozanimod (OZA) 作为住院COVID-19患者治疗的安全性和有效性.
- 确定OZA是否可以改善SARS-CoV-2感染患者的临床结果.
主要方法:
- 一个前性,随机的,开放标签试验试验 (COZI) 涉及三个加拿大医院.
- 需要氧气的COVID-19患者被随机分配到标准护理或标准护理加OZA (14天的增量剂量).
- 主要终点:通过世卫组织调整的临床改善顺序尺度来评估安全性和疗效.
主要成果:
- 23名患者接受了标准护理,20名患者接受了标准护理加上OZA.
- 呼吸支的持续时间,住院时间或临床改善的时间没有显著差异.
- OZA组显示显著降低心率 (P < .0001) 没有影响QT/PR间隔;没有严重的不良药物反应报告.
结论:
- 这是第一个在重症肺炎住院患者中评估SRL实用性的研究.
- 对于患有病毒性肺炎的患者来说,Ozanimod (OZA) 似乎是安全的,具有临床益处的潜力.
- 胸是常见的副作用,但耐受性很好.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
236
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
236
COPD: Management Using Bronchodilators and Corticosteroids
217
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
217
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
Pneumonia IV: Management
338
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
338
Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K


